TP53 and neoplasm: One study suggested that the co-mutation of FAT3 and LRP1B led to significantly prolonged PFS in patients with lung adenocarcinoma treated with immunotherapy [19], and Ying et al. [20] found that patients with squamous cell lung carcinoma and TP53 and TTN (one of the most commonly mutated genes; its role in cancer development is unclear) co-mutation had higher tumor-mutation burden levels and a better response to immunotherapy.